There’s still time to find a solution to the PMPRB problem, stakeholder writes

Recent data from a range of sources confirms what Canada’s innovative medicines industry has been saying for more than three years now: Health Canada’s recent changes to the Patented Medicine Prices Review Board’s (PMPRB) Patented Medicines Regulations will have a negative impact on patientsâ€...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.


Already a Subscriber?

MORE Opinion

RELATED STORIES